| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/15/2007 | WO2007019401A2 Polypeptides useful for appetite suppression |
| 02/15/2007 | WO2007019378A2 Method of treating neurological disorders |
| 02/15/2007 | WO2007018894A2 A kit of lyophilized thrombin and lyophilized fibrinogen used to compound fibrin membrane, and its application |
| 02/15/2007 | WO2007018846A2 Use of interferon- tau for reduction of scar tissue formation |
| 02/15/2007 | WO2007018843A2 Methods and compositions for diagnosis and treatment of influenza |
| 02/15/2007 | WO2007018619A2 Chimeric therapeutic agents |
| 02/15/2007 | WO2007018607A2 Therapeutic uses of artificial nanostructures |
| 02/15/2007 | WO2007018585A2 Process for controlling protein to salt ratio in animal muscle protein composition and protein composition |
| 02/15/2007 | WO2007018546A1 Modulation of cell fates and activities by phthalazinediones |
| 02/15/2007 | WO2007018475A1 Novel anticoagulant polypeptides and complex |
| 02/15/2007 | WO2007018437A1 Methods of modulating apoptosis and platelet production using variants of cytochrome c |
| 02/15/2007 | WO2007018229A1 Treatment of adult t-cell leukemia |
| 02/15/2007 | WO2007018199A1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
| 02/15/2007 | WO2007018198A1 Cancer-rejection antigen peptide derived from hsp105 for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
| 02/15/2007 | WO2007018147A1 Pharmaceutical titanium dioxide composite material of which pharmacological effect can be eliminated by light irradiation |
| 02/15/2007 | WO2007017914A2 Dermonecrotizing protein factors of bacterial origin and related uses in medical field |
| 02/15/2007 | WO2007017637A1 Method for producing recombinant interferon alpha-8 |
| 02/15/2007 | WO2007017284A2 Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 02/15/2007 | WO2007017067A2 Modulators of the melted protein and uses thereof |
| 02/15/2007 | WO2007016961A1 Materials useful for support and/or replacement of tissue and the use thereof for making prostheses |
| 02/15/2007 | WO2007016791A1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 02/15/2007 | WO2007016777A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | WO2007016764A1 Composition and method for prevention and treatment of type i diabetes |
| 02/15/2007 | WO2007016763A1 Peptides targeted to protein kinase c isoforms and uses thereof |
| 02/15/2007 | WO2006125765A3 Acylated insulin with high purity |
| 02/15/2007 | WO2006123354A3 Oral pharmaceutical composition |
| 02/15/2007 | WO2006123122A3 Psk- i and its modulators for the treatment/diagnosis of cancer |
| 02/15/2007 | WO2006121588A3 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 02/15/2007 | WO2006106521A8 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| 02/15/2007 | WO2006104964A3 Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30 |
| 02/15/2007 | WO2006102159A3 Compounds and methods for the treatment of malaria and cancer |
| 02/15/2007 | WO2006094724A3 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| 02/15/2007 | WO2006082304A3 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 02/15/2007 | WO2006081826A3 Survivin peptide vaccine |
| 02/15/2007 | WO2006014253A3 Factor viia variants |
| 02/15/2007 | WO2006011151A3 Vaccine comprising recombinant ct or lt toxin |
| 02/15/2007 | WO2005113059A3 Disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 02/15/2007 | WO2005085323A3 Methods and compositions for treatment of autoimmune diseases |
| 02/15/2007 | WO2005003289A8 Ap1 amine oxidase variants |
| 02/15/2007 | WO2004050023A3 Treatment of diseases and conditions mediated by increased phosphorylation |
| 02/15/2007 | US20070039073 Novel synthetic genes for plant gums |
| 02/15/2007 | US20070039064 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| 02/15/2007 | US20070039063 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 02/15/2007 | US20070037996 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 02/15/2007 | US20070037995 A Substantially Cell Membrane Impermeable Compound And Use Thereof |
| 02/15/2007 | US20070037967 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer |
| 02/15/2007 | US20070037963 Differentially protected orthogonal lanthionine technology |
| 02/15/2007 | US20070037882 Remedy for cerebral neurodegenerative diseases using ppar agonist |
| 02/15/2007 | US20070037863 Dipeptide phenyl ethers |
| 02/15/2007 | US20070037861 Enhanced method of treatment of growth disorders |
| 02/15/2007 | US20070037845 Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof |
| 02/15/2007 | US20070037768 Methods for therapy of neurodegenerative disease of the brain |
| 02/15/2007 | US20070037765 gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 02/15/2007 | US20070037762 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 02/15/2007 | US20070037761 Gene expression inhibition using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR; diabetic retinopathy, age related macular degeneration and many types of cancer |
| 02/15/2007 | US20070037760 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 02/15/2007 | US20070037754 Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide |
| 02/15/2007 | US20070037753 Dipeptide containing an imidazolidinedione or a pyrimidinedione group; inhibitors of the proteasome of cathepsins, especially cathepsin S, or of other proteases |
| 02/15/2007 | US20070037752 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
| 02/15/2007 | US20070037751 Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| 02/15/2007 | US20070037750 Exendin agonist composed of a peptide in which at least one amino acid residue is acylated with a dicarboxylic acid; the amino acid residues are an internal lysine residue, an N-terminal amino acid residue, and/or a C-terminal amino acid residue; treatment of glucagonoma |
| 02/15/2007 | US20070037749 Administering a N-terminus modified polypeptide derived from the fibrin alpha or beta chain; antiinflammatory agent, anticoagulants; transplant rejection; arteriosclerosis |
| 02/15/2007 | US20070037748 Methods of treating diseases with a VEGF antagonist |
| 02/15/2007 | US20070037747 Exendin 4 polypeptide fragment |
| 02/15/2007 | US20070037746 Novel compounds |
| 02/15/2007 | US20070037744 Human cathelicidin antimicrobial peptides |
| 02/15/2007 | US20070037743 Novel conotoxin modulating sodium channels |
| 02/15/2007 | US20070037742 Use of follicle stimulating hormone for reduction of spermatozoa chromosomal aberration in males |
| 02/15/2007 | US20070037741 Novel compositions and methods for the treatment of immune related disease |
| 02/15/2007 | US20070037740 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| 02/15/2007 | US20070037739 Compounds useful in coating stents to prevent and treat stenosis and restenosis |
| 02/15/2007 | US20070037738 Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions |
| 02/15/2007 | US20070037737 Composition and method for the repair and regeneration of cartilage and other tissues |
| 02/15/2007 | US20070037736 Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury |
| 02/15/2007 | US20070037735 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/15/2007 | US20070037280 Method for generating primate trophoblasts |
| 02/15/2007 | US20070037253 18-Residue dimerized peptide designated PIP [59-67] dimer, having dual inhibitory activity against secretory phospholipase A2 (sPLA2) and matrix metalloproteinases (MMPs); acute pancreatitis; infection; neurodegenerative disease; neuronal excitotoxicity |
| 02/15/2007 | US20070037249 Molecules that block viral infectivity and methods of use thereof |
| 02/15/2007 | US20070037211 Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of mycobacterium tuberculosis |
| 02/15/2007 | US20070037210 Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same |
| 02/15/2007 | US20070037209 a fragment derived from the MET ectodomain in monomer form binds to hepatocyte growth factor/scatter factor (HGF/SF) either in the presence or absence of heparin; method for determining whether an agent binds to a MET ectodomain fragment in monomeric form |
| 02/15/2007 | US20070037206 Human secreted proteins |
| 02/15/2007 | US20070037202 Potentiation of cancer therapies by ZNF217 inhibition |
| 02/15/2007 | US20070037158 Methods of modulating bone growth, bone remodeling and adiposity |
| 02/15/2007 | US20070037147 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/15/2007 | US20070037141 comprise DP178 peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein; inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells |
| 02/15/2007 | US20070036815 Ricin-like toxins for treatment of cancer |
| 02/15/2007 | US20070036813 Expression vector comprising nucleotide sequences coding endothelial growth factor protein for use in prevention and treatment of cell proliferative and eye disorders |
| 02/15/2007 | US20070036812 polypeptide with binding to antigen and is recognized by cytotoxic T lymphocytes; use as cancer vaccine |
| 02/15/2007 | US20070036810 Cyclic amp response element activator proteins and uses related thereto |
| 02/15/2007 | US20070036806 have an increased half-life, decreased immunogenicity, and reduce effector activity; diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying |
| 02/15/2007 | US20070036790 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036789 Neutralizable Epitope of HGF and Neutralizing Antibody Binding to the Same |
| 02/15/2007 | US20070036785 Pharmaceutical composition for treatment of diseases caused by IL-6 production |
| 02/15/2007 | US20070036782 Apo-2 ligand |
| 02/15/2007 | US20070036780 Modified proteins, designer toxins, and methods of making thereof |
| 02/15/2007 | US20070036777 Stabilized pancreas product |
| 02/15/2007 | US20070036776 Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties |
| 02/15/2007 | US20070036775 Method of modulating or examining Ku70 levels in cells |
| 02/15/2007 | US20070036768 Systems and methods for treating patients with processed lipoaspirate cells |